Clinical Trial Update: A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Avastin (bevacizumab) in combination with low-dose interferon in metastatic renal cell carcinoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Interferon Alfa (interferon alfa)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-05-27